These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 37230531

  • 21. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 22. Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.
    Zhao G, Ji B.
    AJR Am J Roentgenol; 2022 Sep; 219(3):386-395. PubMed ID: 35441529
    [Abstract] [Full Text] [Related]

  • 23. Diagnostic efficacy of [99mTc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis.
    Wang Q, Ketteler S, Bagheri S, Ebrahimifard A, Luster M, Librizzi D, Yousefi BH.
    BMC Cancer; 2024 Aug 08; 24(1):982. PubMed ID: 39118101
    [Abstract] [Full Text] [Related]

  • 24. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep 08; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 25. Strong Correlation Between SUVmax on PSMA PET/CT and Numeric Drop-In γ-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    Berrens AC, Sorbi MA, Donswijk ML, de Barros HA, Azargoshasb S, van Oosterom MN, Rietbergen DDD, Bekers EM, van der Poel HG, van Leeuwen FWB, van Leeuwen PJ.
    J Nucl Med; 2024 Apr 01; 65(4):548-554. PubMed ID: 38485277
    [Abstract] [Full Text] [Related]

  • 26. Diagnostic value of [99mTc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer.
    Farkas I, Sipka G, Bakos A, Maráz A, Bajory Z, Mikó Z, Czékus T, Urbán S, Varga L, Pávics L, Besenyi Z.
    Ther Adv Med Oncol; 2024 Apr 01; 16():17588359231221342. PubMed ID: 38249326
    [Abstract] [Full Text] [Related]

  • 27. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 28. The diagnostic accuracy of 68Ga-PSMA PET/CT versus 99mTc-MDP bone scintigraphy for identifying bone metastases in persons with prostate cancer: A systematic review.
    Daniels H, Gilbert R, Bonin L.
    J Med Imaging Radiat Sci; 2023 Sep 15; 54(3):545-555. PubMed ID: 37211439
    [Abstract] [Full Text] [Related]

  • 29. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb 15; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 30. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
    García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.
    Am J Nucl Med Mol Imaging; 2018 Feb 15; 8(5):332-340. PubMed ID: 30510850
    [Abstract] [Full Text] [Related]

  • 31. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study.
    Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L.
    J Nucl Med; 2021 Aug 01; 62(8):1075-1081. PubMed ID: 33277398
    [Abstract] [Full Text] [Related]

  • 32. [99mTc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study.
    Li B, Ding X, Duan L, Shi J, Tang M, Zhang J, Zhao Z, Wu X, Gao Y.
    Front Endocrinol (Lausanne); 2024 Aug 01; 15():1326858. PubMed ID: 38449842
    [Abstract] [Full Text] [Related]

  • 33. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 34. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
    Lengana T, Lawal I, Janse Van Rensburg C, Mokoala K, Moshokoa E, Mazibuko S, Van de Wiele C, Maes A, Vorster M, Sathekge MM.
    Nuklearmedizin; 2022 Apr 26; 61(2):120-129. PubMed ID: 35421900
    [Abstract] [Full Text] [Related]

  • 35. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer.
    Ghaedian T, Abdinejad M, Nasrollahi H, Ghaedian M, Firuzyar T.
    Nucl Med Commun; 2023 Oct 01; 44(10):864-869. PubMed ID: 37464793
    [Abstract] [Full Text] [Related]

  • 36. 67 Ga-PSMA I&T for Radioguided Surgery of Lymph Node Metastases in Patients With Biochemical Recurrence of Prostate Cancer.
    Winkens T, Berger FP, Foller S, Greiser J, Groeber S, Grimm MO, Freesmeyer M, Kuehnel C.
    Clin Nucl Med; 2023 Jul 01; 48(7):600-607. PubMed ID: 37145416
    [Abstract] [Full Text] [Related]

  • 37. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 01; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients.
    Özülker F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 May 01; 38(2):100-105. PubMed ID: 30514659
    [Abstract] [Full Text] [Related]

  • 39. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan 01; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 40. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
    Schmidkonz C, Götz TI, Atzinger A, Ritt P, Prante O, Kuwert T, Bäuerle T, Goebell P, Cordes M.
    Clin Nucl Med; 2020 Aug 01; 45(8):e349-e357. PubMed ID: 32558706
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.